New Parkinson’s Disease Clinical Trials Are Currently Enrolling Patients
Parkinson's disease clinical trials
The characteristic symptoms of Parkinson’s disease (PD) are caused by the degeneration of dopamine-producing neurons in the brain. One development in current Parkinson’s research is looking at motor centers in the brain that do not receive enough of a compound called gamma-aminobutyric acid (GABA).
This investigational study is designed to determine if intracranial administration of glutamic acid decarboxylase (GAD), the enzyme that aids in the production of GABA, will help restore normal function in the brain and alleviate the symptoms associated with Parkinson’s disease.
This is a double-blind, randomized, placebo-controlled study. Study participants will be selected randomly to receive either rAAV-GAD, a recombinant viral delivery vector that contains the gene that makes GAD, or sterile saline by infusion into brain cells using an investigational device via a stereotactic neurosurgery procedure. These study participants will receive the study drug or sterile saline, study-related monitoring, and care from study doctors at no cost.
Register to view a live Webcast about this clinical trial for Parkinson’s disease with Michael G. Kaplitt, MD, PhD.
Learn more about this study and how your patients might participate
Register to receive more information on this study and to view an informative Webcast about this new investigational clinical trial for Parkinson’s disease.
If you have PD, learn more about this clinical trial
Register to receive more information on this study and to view an informative Webcast about this investigational clinical trial for Parkinson’s disease.
Terms and Conditions
Neurologix, Inc. is the sponsor of this study. Neurologix™ is a trademark of Neurologix, Inc. All rights reserved. Intended for US viewers only.